3210 Merryfield Row
32 articles with Forge Therapeutics
Forge Therapeutics, Inc. (Forge), a biotechnology company developing novel anti-infectives targeting bacterial and viral metalloenzymes, announced today that Andrew Tomaras, Ph.D. has been appointed as Chief Scientific Officer.
5/5/2021April showers bring May dollars. Here's whose cash gardens are really blooming this week in the life sciences world.
1/11/2021The new year began with a fairly low level of clinical trial news. Here’s a look.
Forge Therapeutics, Inc. (Forge) announced today that they have entered into a research collaboration and option agreement with Hoffmann-La Roche Ltd. (Roche) to license FG-LpxC LUNG, a novel antibiotic for the treatment of serious lung infections attributed to antibiotic-resistant Gram-negative bacteria including Pseudomonas aeruginosa.
Forge Therapeutics Receives Notice Of Allowance From U.S. Patent And Trademark Office Covering Novel Chemistry Targeting LpxC For The Treatment Of Gram-Negative Bacterial Infections
Forge Therapeutics, Inc. (Forge), a biotechnology company developing novel medicines targeting metalloenzymes, announced today that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for its patent application directed to compositions of matter and methods of use of certain 'non-hydroxamate' inhibitors of LpxC for the treatment of Gram-negative bacterial infections.
Forge Therapeutics, Inc. (Forge) and Basilea Pharmaceutica International Ltd. (Basilea), a wholly-owned subsidiary of Basilea Pharmaceutica Ltd. [SIX: BSLN], announced today that they have entered into a research collaboration and license agreement to discover, develop, and commercialize novel antibiotic classes.
Presentation will focus on Forge's novel chemistry platform, BLACKSMITH, and its therapeutic applications
Forge Receives Second CARB-X Award For Up To $11.1M To Accelerate Development Of Novel Antibiotic To Treat Lung Infections
Forge Therapeutics, Inc. announced today that it has received a second CARB-X award for developing a novel antibacterial therapeutic agent.
Forge Achieves CARB-X Milestone To Advance Its LpxC Antibiotic To Treat Infections Caused By The World's Deadliest 'Superbugs'
-Technical milestone achievement and program advancement from initial round of 'Powered by CARB-X' products-
Forge Announces Oral Presentation On Development Of Novel Antibiotics At The 28th Annual ECCMID Meeting
Forge Therapeutics, Inc. announced that David Puerta, Ph.D., Forge's COO and VP of Discovery, will discuss Forge's emerging initiatives in antibacterial R&D in an oral presentation at the 28th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) meeting being held April 21-24, 2018 in Madrid, Spain.
Forge Therapeutics and Collaborators From Evotec and USC Present New Efficacy Data At 2017 Keystone Symposia Conference
Forge announced new efficacy data today on Forge's LpxC antibiotic program at the 2017 Keystone Symposia Conference "Antimicrobials and Resistance: Opportunities and Challenges" during an oral presentation and a poster session.
Forge & Evotec Expand Strategic Alliance With Launch Of BLACKSMITH Platform To Discover Novel Metalloenzyme Inhibitors Across Broad Therapeutic Areas
Forge announced today that the companies have expanded their existing strategic alliance and launched the BLACKSMITH platform to discover a broader range of therapeutics targeting metalloenzymes.
Forge Therapeutics And Evotec AG Present Efficacy Data For LpxC Inhibitor In Urinary Tract, Lung, Thigh, And Abdominal Infection Models At ASM ESCMID 2017
Forge Therapeutics And Evotec AG To Present Preclinical Data On Novel Antibiotic Program At 2017 ASM/ESCMID Conference
Forge Therapeutics Forms Scientific Advisory Board With World Renowned Antibiotic And Drug Development Experts
Forge Therapeutics And Evotec AG Present First Efficacy Data For LpxC Inhibitor In UTI Model At ASM Microbe 2017
Forge Therapeutics Raises $15M Series A Financing To Develop First Novel Gram-Negative Antibiotic In Decades
Forge Therapeutics Wins Powered By CARB-X Research Award Of $8.8M To Accelerate Development Of Its LpxC Antibiotic To Kill The World's Deadliest 'Superbugs'